Renal Failure Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment (Dialysis, Kidney Transplantation, Drug Therapy, Others), By End Use (Hospitals, Specialty Clinics, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 111.78 Billion
CAGR (2026-2031)	9.91%
Fastest Growing Segment	Dialysis
Largest Market	North America
Market Size (2031)	USD 197.05 Billion

Market Overview

The Global Renal Failure Treatment Market will grow from USD 111.78 Billion in 2025 to USD 197.05 Billion by 2031 at a 9.91% CAGR. Renal failure treatment comprises the medical procedures and therapeutic interventions, primarily dialysis and kidney transplantation, utilized to manage the acute or chronic loss of renal function. The market’s expansion is fundamentally driven by the rising global incidence of lifestyle-related conditions such as diabetes and hypertension, which are the primary precursors to end-stage renal disease. Furthermore, the growing geriatric population necessitates increased access to long-term renal replacement therapies, ensuring sustained demand for both hemodialysis and peritoneal dialysis modalities independent of temporary market trends.

However, the market faces a substantial challenge regarding the critical shortage of donor organs, which severely restricts the volume of transplant procedures and forces reliance on costly maintenance dialysis. This supply-demand imbalance creates a significant bottleneck in providing definitive curative care. According to the National Kidney Foundation, in 2024, there were 90,323 patients on the kidney transplant waiting list in the United States, illustrating the profound disparity between the availability of organs and the escalating number of patients requiring treatment.

Key Market Drivers

The escalating global incidence of diabetes and hypertension acts as the primary catalyst for the renal failure treatment market, directly expanding the pool of patients requiring long-term care. As urbanization and sedentary lifestyles proliferate, the prevalence of these chronic conditions drives the progression of Chronic Kidney Disease (CKD) to End-Stage Renal Disease (ESRD), necessitating immediate therapeutic intervention. This continuous influx of patients is evident in the operational metrics of major providers, reflecting the substantial and growing demand for renal replacement therapies. According to DaVita Inc., February 2025, in the '4th Quarter 2024 Results', the company provided dialysis services to approximately 281,100 patients, illustrating the profound burden of renal conditions on healthcare systems. The scale of this demand is further highlighted by the immense volume of procedures performed globally; according to Fresenius Medical Care, in 2024, the company performed approximately 48 million dialysis treatments worldwide.

Increasing adoption of home-based dialysis modalities is simultaneously reshaping market dynamics, driven by technological advancements and a clinical emphasis on improving patient quality of life. Innovations in portable dialysis machines and remote monitoring systems have made home treatment a viable and often preferred alternative to in-center care, offering patients greater autonomy and reduced exposure to clinical infections. This structural shift is supported by robust longitudinal data indicating a preference for flexible treatment options. According to the Medical Education Institute, January 2025, in the 'Home Dialysis Updates from the 2024 USRDS Annual Data Report', the proportion of prevalent patients utilizing home hemodialysis increased by 60% over the analyzed period, signaling a significant transformation in treatment delivery models. Consequently, manufacturers are accelerating the development of user-friendly peritoneal and home hemodialysis solutions to capitalize on this expanding segment.

Download Free Sample Report

Key Market Challenges

The critical shortage of donor organs functions as a significant restraint on the global renal failure treatment market by capping the volume of transplant procedures that can be performed. This scarcity limits the expansion of the surgical segment and restricts the adoption of post-transplant therapies, which are integral components of the market value chain. Because the supply of organs is inelastic compared to the rising incidence of renal disease, healthcare providers are unable to scale curative operations to meet patient needs. This physical limitation creates a bottleneck that prevents the market from fully capitalizing on the demand for permanent renal replacement solutions.

Consequently, the severe gap between supply and demand results in extended waiting periods that stall patient movement through the treatment ecosystem. According to the United Network for Organ Sharing, in 2024, statistics revealed that only approximately 27,000 kidney transplants were performed in the United States during the preceding year, covering a small fraction of the total requirement. This limitation forces a continued dependence on maintenance dialysis, thereby hampering the growth of the transplant sector and stifling the potential for broader adoption of definitive curative treatments.

Key Market Trends

Expanded clinical use of SGLT2 inhibitors and GLP-1 agonists is fundamentally altering the treatment landscape by shifting focus from renal replacement to disease progression delay. This trend is characterized by the widespread adoption of pharmaceutical interventions that mitigate the risk of adverse renal outcomes in patients with Chronic Kidney Disease (CKD) and Type 2 diabetes. The market is witnessing a surge in the prescription of these therapies as clinical guidelines evolve to prioritize organ protection, effectively expanding the addressable market beyond traditional dialysis populations. This shift is substantiated by robust financial performance in the segment; according to Pharmaceutical Technology, August 2025, in the 'Novo Nordisk's diabetes and weight loss drug sales growth decelerates' article, sales for the company's diabetes and obesity care portfolio, which includes key renal-protective agents, grew 16% to DKK 145.4 billion in the first half of 2025.

Simultaneously, the integration of artificial intelligence for predictive renal analytics is transforming patient management through data-driven risk assessment and early intervention strategies. Healthcare providers are increasingly deploying AI-enabled diagnostic platforms to identify high-risk patients and optimize care pathways, thereby reducing the incidence of emergency dialysis starts. This technological adoption is being accelerated by improved reimbursement structures for digital diagnostic tools, which incentivizes clinical uptake. The growing commercial viability of these advanced analytics solutions is evident in recent financial disclosures; according to Renalytix plc, March 2025, in the 'Half Year Report', the company recorded that commercial insurance reimbursed testing revenue increased by 28% compared to the first half of the previous fiscal year, reflecting the rising utilization of prognostic testing in clinical practice.

Segmental Insights

The Dialysis segment represents the fastest growing category in the Global Renal Failure Treatment Market due to the critical gap between organ donation supply and the rising demand for transplants. With the increasing prevalence of end-stage renal disease, dialysis remains the primary life-sustaining therapy for patients awaiting permanent solutions. This dependency is further reinforced by favorable reimbursement policies from organizations like the Centers for Medicare and Medicaid Services, which encourage the adoption of treatment modalities. Consequently, the limited availability of viable alternatives ensures that dialysis continues to dominate market expansion globally.

Regional Insights

North America maintains a leading position in the global renal failure treatment market due to the rising incidence of chronic kidney disease and well-established healthcare systems. The region benefits from robust research initiatives and the presence of key industry players that drive therapy development. A supportive regulatory environment, overseen by the United States Food and Drug Administration, facilitates the timely approval of new dialysis technologies and pharmaceuticals. Furthermore, comprehensive reimbursement structures provided by the Centers for Medicare & Medicaid Services ensure broad patient access to essential renal care, thereby sustaining high market demand.

Recent Developments

• In September 2024, Travere Therapeutics announced that the U.S. FDA granted full approval for Filspari, its oral, non-immunosuppressive treatment for IgA nephropathy. This regulatory decision upgraded the drug's previous accelerated approval status, following the submission of positive long-term confirmatory results that showed the medication significantly slowed kidney function decline over two years compared to an active comparator. The full approval allowed the company to market the treatment more broadly to patients at risk of disease progression, successfully removing specific urine protein level requirements from the label and positioning the drug as a foundational care option.
• In September 2024, Boehringer Ingelheim, in collaboration with Healthy.io and Geisinger, released milestone data concerning chronic kidney disease (CKD) screening. Presented at a scientific session, the study results indicated that using a smartphone-enabled home test significantly increased adherence to testing guidelines among at-risk individuals compared to traditional standard-of-care methods. The partnership aimed to improve the early identification of CKD in patients with hypertension and diabetes, demonstrating the potential of integrating digital technology with clinical care to enhance disease management and potentially delay the progression to renal failure.
• In August 2024, Novartis received accelerated approval from the U.S. FDA for Fabhalta, a first-in-class complement inhibitor indicated for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). The approval was based on interim analysis data from a Phase III study, which demonstrated a clinically meaningful reduction in proteinuria compared to a placebo. This development marked a significant addition to the company's renal pipeline, addressing a critical unmet need for patients at risk of rapid disease progression by targeting the alternative complement pathway of the immune system to help preserve kidney function.
• In February 2024, Fresenius Medical Care announced that it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new 5008X Hemodialysis System. This regulatory milestone enabled the company to introduce high-volume hemodiafiltration therapy to patients in the United States, a treatment modality that had already been widely utilized across Europe. The clearance paved the way for the company to initiate clinical evaluations and user studies within the U.S. market, setting the stage for a planned broad commercial launch of the system in 2025 to replace the substantial installed base of conventional in-center hemodialysis machines.

Key Market Players

• NIPRO
• Fresenius Medical Care Holdings, Inc
• Baxter International, Inc
• Medtronic Plc
• B. Braun SE
• Asahi Kasei Medical Co., Ltd.
• AbbVie Inc.
• JMS Co.Ltd
• Nikkiso Co., Ltd
• AstraZeneca Plc

By Treatment	By End Use	By Region
Dialysis Kidney Transplantation Drug Therapy Others	Hospitals Specialty Clinics Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Renal Failure Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Renal Failure Treatment Market, By Treatment:

• Dialysis
• Kidney Transplantation
• Drug Therapy
• Others

• Renal Failure Treatment Market, By End Use:

• Hospitals
• Specialty Clinics
• Others

• Renal Failure Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE